Separately, in their guidance, NICE recommends pertuzumab, with intravenous trastuzumab and chemotherapy, for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults, only if they have lymph node-positive disease and the company provides it according to the commercial arrangement.